Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2020
June 2020, Vol 11, No 3
June 2020, Vol 11, No 3
Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer
FDA Approvals, News & Updates
June 2020, Vol 11, No 3
On April 15, 2020, the FDA approved mitomycin gel (Jelmyto; UroGen Pharma), an alkylating drug as the first treatment for patients with low-grade upper-tract urothelial cancer. Mitomycin is a combination of chemotherapy and a sterile hydrogel that stops the transcription of DNA into RNA and halts the synthesis of protein, thereby blocking the ability of cancer cells to multiply. The FDA granted mitomycin gel priority review, breakthrough therapy, fast track, and orphan drug designations.
Read Article
Capecitabine Improves Outcomes in TNBC When Added to Other Systemic Therapy
By
Phoebe Starr
Breast Cancer
June 2020, Vol 11, No 3
San Antonio, TX—Although capecitabine (Xeloda) is approved for metastatic breast cancer, it is not clear whether it should be used in early breast cancer, and its optimal role remains to be established. A large meta-analysis sheds some light on this issue, demonstrating that capecitabine improves disease-free survival (DFS) and overall survival (OS) for patients with triple-negative breast cancer (TNBC) when added to other systemic therapies, but not as a substitute for other therapies.
Read Article
Androgen-Deprivation Therapy Seldom Used with Radiation in Localized Prostate Cancer
By
Wayne Kuznar
Prostate Cancer
June 2020, Vol 11, No 3
San Francisco, CA—Today, patients who receive stereotactic body radiation therapy (SBRT) for intermediate- or high-risk localized prostate cancer are not receiving concurrent androgen-deprivation therapy (ADT), despite national guideline recommendations that support the concurrent use of ADT with radiation therapy.
Read Article
Immune Checkpoint Inhibitor Does Not Improve Outcomes in Metastatic Prostate Cancer
By
Phoebe Starr
Prostate Cancer
June 2020, Vol 11, No 3
No improvement in survival or in any key secondary end point was observed when the checkpoint inhibitor atezolizumab (Tecentriq) was added to enzalutamide (Xtandi) for the treatment of metastatic castration-resistant prostate cancer (CRPC) in the phase 3 IMbassador250 trial. The study results were presented at the 2020 American Association for Cancer Research virtual annual meeting.
Read Article
Cancer Research During and After COVID-19
AVBCC COVID-19 Webcast Series Coverage
,
COVID-19
June 2020, Vol 11, No 3
The COVID-19 crisis has far-reaching implications for research in healthcare. A panel of experts explored the detrimental effects of the pandemic on the career development of research students, potential changes in the availability of clinical trials, and the anticipated shortfall of future funding for healthcare research. The session was moderated by Rob Butcher, Chief Executive Officer, Swim Across America, a charity that raises money for cancer research and funds 57 laboratories around the country.
Read Article
More Genetic Testing Needed in Breast Cancer
By
Meg Barbor, MPH
Breast Cancer
June 2020, Vol 11, No 3
Miami, FL—With too much red tape regarding genetic (ie, hereditary) testing, not enough people are being identified before they have breast cancer, according to Kevin Hughes, MD, FACS, Co-Director, Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Boston.
Read Article
ctDNA Potential Biomarker for MRD Positivity and Relapse After Surgery in Patients with NSCLC
By
Phoebe Starr
AACR Meeting Highlights
June 2020, Vol 11, No 3
Data from the TRACERx lung study suggest that circulating tumor DNA (ctDNA) may be a biomarker for the detection of postsurgical minimal residual disease (MRD) in patients with non–small-cell lung cancer (NSCLC), suggesting which patients are at increased risk for disease relapse and will require more aggressive adjuvant therapy.
Read Article
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangiocarcinoma with FGFR2 Biomarker
By
Loretta Fala
Cholangiocarcinoma
June 2020, Vol 11, No 3
Cholangiocarcinoma (CCA), a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine, affects 2000 to 3000 individuals annually in the United States.
1
The disease most often affects older people aged ≥65 years and occurs slightly more frequently in men than in women.
Read Article
Atezolizumab-Bevacizumab Combo Improves Survival and Quality of Life in Unresectable Liver Cancer
By
Wayne Kuznar
Gastric Cancer
June 2020, Vol 11, No 3
San Francisco, CA—The combination of atezolizumab (Tecentriq) immunotherapy plus bevacizumab (Avastin) improves survival as well as significantly delaying deterioration in quality of life compared with the current standard of the targeted therapy sorafenib (Nexavar) in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read Article
Promising 3-Drug Regimen for Advanced Gastric Cancer, Regardless of PD-L1 Expression
By
Wayne Kuznar
Gastric Cancer
June 2020, Vol 11, No 3
San Francisco, CA—Second-line treatment with a 3-drug regimen that included the PD-1 inhibitor nivolumab (Opdivo), the VEGF receptor antagonist ramucirumab (Cyramza), and chemotherapy with the taxane paclitaxel, showed durable and impressive response rates, regardless of PD-L1 expression, in patients with advanced gastric cancers. Shuichi Hironaka, MD, PhD, Chiba Cancer Center, Japan, reported the study results at the 2020 Gastrointestinal Cancers Symposium.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma